Satellos Bioscience Past Earnings Performance
Past criteria checks 0/6
Satellos Bioscience's earnings have been declining at an average annual rate of -36%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 171.6% per year.
Key information
-36.0%
Earnings growth rate
2.3%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | 171.6% |
| Return on equity | -79.0% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
No updates
Recent updates
Is Satellos Bioscience (TSE:MSCL) In A Good Position To Deliver On Growth Plans?
Oct 07
We're Hopeful That Satellos Bioscience (TSE:MSCL) Will Use Its Cash Wisely
Apr 11Here's Why We're Not Too Worried About Satellos Bioscience's (CVE:MSCL) Cash Burn Situation
Dec 22Will Satellos Bioscience (CVE:MSCL) Spend Its Cash Wisely?
Apr 08Revenue & Expenses Breakdown
How Satellos Bioscience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -23 | 9 | 0 |
| 31 Mar 24 | 0 | -21 | 8 | 0 |
| 31 Dec 23 | 0 | -16 | 7 | 0 |
| 30 Sep 23 | 0 | -14 | 5 | 0 |
| 30 Jun 23 | 0 | -13 | 4 | 0 |
| 31 Mar 23 | 0 | -11 | 4 | 0 |
| 31 Dec 22 | 0 | -11 | 5 | 0 |
| 30 Sep 22 | 0 | -9 | 4 | 0 |
| 30 Jun 22 | 0 | -18 | 4 | 0 |
| 31 Mar 22 | 0 | -17 | 3 | 0 |
| 31 Dec 21 | 0 | -16 | 3 | 0 |
| 30 Sep 21 | 0 | -13 | 2 | 0 |
| 30 Jun 21 | 0 | -2 | 1 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
| 31 Dec 19 | 0 | -2 | 1 | 0 |
Quality Earnings: MSCL is currently unprofitable.
Growing Profit Margin: MSCL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: MSCL is unprofitable, and losses have increased over the past 5 years at a rate of 36% per year.
Accelerating Growth: Unable to compare MSCL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MSCL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Return on Equity
High ROE: MSCL has a negative Return on Equity (-79.04%), as it is currently unprofitable.